TTPH - Tetraphase Pharma Summary, Stock Quote and News

1.500 -0.08 (-5.06%)

After Hours 1.58 (%)

Data as of Dec 14, 2018

Prev. Close 1.58
Price Open 1.56
Volume 541,452
Day's Range 1.485 - 1.58
52 Wk Range 1.545 - 6.9
50 Day Moving Avg. 2.08
PE Ratio 0
Shares Outstanding 53.63M
Market Cap 80.44M

Trade TTPH stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
9/06/18	WBB Securities	Upgrades	Speculative BuyBuy	0.0
8/28/18	B. Riley FBR	Maintains	BuyBuy	7.0
8/28/18	H.C. Wainwright	Maintains	BuyBuy	7.0

Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018 Benzinga NewsdeskWed, 28 Nov 2018 11:54:28 -0500
Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018 Benzinga NewsdeskTue, 27 Nov 2018 11:26:01 -0500
Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018 Benzinga NewsdeskTue, 20 Nov 2018 09:12:31 -0500
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results Shanthi RexalineThu, 15 Nov 2018 08:10:31 -0500
76 Biggest Movers From Yesterday Lisa LevinThu, 15 Nov 2018 04:20:30 -0500
58 Stocks Moving In Wednesday's Mid-Day Session Lisa LevinWed, 14 Nov 2018 12:49:52 -0500
The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall Shanthi RexalineFri, 09 Nov 2018 07:32:16 -0500
Tetraphase Pharma Q3 EPS $(0.37) Misses $(0.36) Estimate Benzinga NewsdeskThu, 08 Nov 2018 16:03:14 -0500
Tetraphase Pharmaceuticals To Announce Data From Post-Hoc Analysis Of Phase 3 Trials Demonstrating Efficacy Of XERAVA October 20-23 Benzinga_NewsdeskTue, 23 Oct 2018 05:36:36 -0500
20 Stocks Moving In Friday's Pre-Market Session Lisa LevinFri, 12 Oct 2018 07:20:31 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference Globe NewswireDec 05, 2018
Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra — New Horizons, Emerging Trends, and Upcoming Developments Globe NewswireNov 29, 2018
Technological Advancements Show Growth in the Hospital Acquired Infection Control Market PRNewswireNov 16, 2018
Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Globe NewswireNov 08, 2018
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences Globe NewswireNov 07, 2018
Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call Globe NewswireNov 01, 2018
Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials Demonstrating Efficacy of XERAVA™ (eravacycline) in Obese and Renally Impaired Patients with Complicated Intra-Abdominal Infections Globe NewswireOct 23, 2018
Consolidated Research: 2018 Summary Expectations for Vuzix, BCE, Tetraphase Pharmaceuticals, T2 Biosystems, TPG Specialty Lending, and Jianpu Technology — Fundamental Analysis, Key Performance Indications Globe NewswireOct 22, 2018
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States Globe NewswireOct 11, 2018
Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018 Globe NewswireOct 08, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

All Eyes On Walmart, Volkswagen And A Jedi Contract (Stocks To Watch Podcast) Seeking AlphaNov 11, 2018
Stocks To Watch: All Eyes On Walmart, Volkswagen And A Jedi Contract Seeking AlphaNov 10, 2018
Tetraphase Pharmaceuticals' (TTPH) CEO Guy MacDonald on Q3 2018 Results - Earnings Call Transcript Seeking AlphaNov 08, 2018
Tetraphase Pharmaceuticals misses by $0.01, misses on revenue Seeking AlphaNov 08, 2018
Premarket Gainers as of 9:05 am (10/12/2018) Seeking AlphaOct 12, 2018
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States GuruFocusOct 11, 2018
After Hours Gainers / Losers (10/11/2018) Seeking AlphaOct 11, 2018
Tetraphase launches eravacycline in U.S.; shares up 13% after hours Seeking AlphaOct 11, 2018
Tetraphase Pharmaceuticals announces positive data from clinical trials of XERAVA and TP-6076 at IDWeek 2018 Seeking AlphaOct 08, 2018
Tetraphase: A Strong Player In The Antibiotic Resistance Field Seeking AlphaOct 04, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2018	EST	Actual	Surprise
EPS:	-0.36	-0.37	-0.01
Rev:	1.87M	1.15M	-719.00K

Q4 2018	EST	Actual	Surprise
EPS:	Expected 2019-03-05
Rev:	Expected 2019-03-05

Company Profile

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

Tetraphase Pharma TTPH:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Tetraphase Pharma TTPH:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners